Navigation Links
Intarcia Supports American Diabetes Association Call For Independent Review Of Incretin-Based Therapies
Date:6/13/2013

p>About the FREEDOM Program
The FREEDOM program is designed to evaluate the safety and efficacy of ITCA 650 (continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes. Intarcia expects to enroll greater than 4,000 patients at more than 500 clinical trial sites in more than 30 countries. The clinical studies will cover a broad range of patients whose diabetes is not controlled by oral anti-diabetes medications including metformin and metformin-based combinations. FREEDOM-1 is a U.S.-only, placebo-controlled, double-blind study comparing ITCA 650 doses of 40 mcg/d and 60 mcg/d to placebo; the FREEDOM-2 study will be a 500-patient, global, active-comparator controlled, double-blind, double-dummy study in patients on metformin only, comparing ITCA 650 20 mcg/d for 13 weeks plus ITCA 650 60 mcg/d for 39 weeks to patients taking sitagliptin (Januvia®, Merck); FREEDOM-CVO is a global, placebo-controlled cardiovascular outcomes study that will examine the safety of ITCA 650 at 60 mcg/d vs. placebo in approximately 3,000 patients on a variety of approved anti-diabetes therapies.

About ITCA 650
ITCA 650 (continuous subcutaneous delivery of exenatide) is being developed for the treatment of type 2 diabetes. The investigational therapy employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted subcutaneously to provide continuous and consistent drug therapy, and the company's proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for extended periods of time.

Data from Intarcia's ITCA 650 Phase 2 program have demonstrated significant and sustained reductions in HbA1c and body weight over 48 weeks of treatment with a marked reduction in the GI adverse events typically associated with the self-injection products in this class. ITCA 650 is an investigational new therapy and is not currently approve
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intarcia Appoints Owen Hughes Chief Business Officer and Head of Corporate Development
2. Intarcia Enrolls First Patients in "FREEDOM" Global Phase 3 Program for ITCA 650 in Type 2 Diabetes
3. Pharmaceutics International, Inc. (Pii) Supports University Pharmaceutical Technology Education and Research
4. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
5. U.S. Government Supports Phase 3 Study of Bavarian Nordics Smallpox Vaccine
6. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
7. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
8. Ventana Supports World Patient Safety Day, July 25
9. eCardio Supports the Carolinas HealthCare Foundation Through Grant for Heart Of A Champion Day
10. Verify Brand Supports the Proposed FDA Unique Device Identification (UDI) System for Medical Devices
11. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015  MEI Pharma, ... the clinical development of novel therapies for cancer, announced today ... Executive Officer, will present at the 2015 Wedbush PacGrow Healthcare ... time from Le Parker Meridien in ... can be accessed at www.meipharma.com . A replay will ...
(Date:8/4/2015)... 2015  Delcath Systems, Inc. (NASDAQ: DCTH ), ... oncology with an emphasis on the treatment of primary ... data from studies in Europe ... CHEMOSAT ® Delivery System (CHEMOSAT) will be presented at ... which will be held in Marseille, France ...
(Date:8/4/2015)... DIEGO , Aug. 4, 2015 ... three-dimensional biology company focused on delivering scientific and ... that the Company has hired Paul Gallant ... vitro tissue service and product business. Mr. Gallant has ... experience in the drug discovery industry, most recently ...
Breaking Medicine Technology:MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 2Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 3Delcath Announces Acceptance of Abstracts for Presentation at the European Association of Dermato Oncology Annual Congress 4Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3
... CITY, Feb. 21, 2012 Genomma Lab Internacional, S.A.B. de ... a non-binding proposal to acquire all of the outstanding shares ... ) common stock for $16.60 dollars per share in cash. ... including Prestige,s net debt. Genomma,s all-cash proposal ...
... Corporation (NYSE: SHP ) ("ShangPharma" or the ... development outsourcing company, today announced that it will attend ... in Boston, Massachusetts from March 5-7, 2012. ... Relations of ShangPharma, will present at the conference and ...
Cached Medicine Technology:Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 3Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 4Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 5
(Date:8/4/2015)... ... 04, 2015 , ... Bayco Products, Inc. announces a new industrial-grade LED Dual-LightTM ... hard hats that have a flip-up face shield. The sleek contours of the new ... having to remove their headlamp when raising or lowering their face shield or visor. ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... the United States, Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors ... and will save lives," Dr. Carmona said. "I strongly believe in the mission ...
(Date:8/4/2015)... Diego, CA (PRWEB) , ... August 04, 2015 ... ... the Rise of Local Food,” scheduled for Nov. 3 – 4, 2015, at ... grow food sustainably, create new businesses, improve food access, and manage resources efficiently ...
(Date:8/4/2015)... ... August 04, 2015 , ... Many men are confused about the safety ... is standing up as a voice of authority for men seeking accurate information about ... with special experience and expertise in the safe and effective treatment of low testosterone. ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... They say ... better understand certain health conditions, pictures and medical art can be essential. StayWell, a ... providers. , Krames Patient Education solutions have been used by physicians and other ...
Breaking Medicine News(10 mins):Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 2Health News:StayWell Offers Instant Downloads, Licensing of Medical Art to Improve Patient Education 3
... radioactive liquid to guide surgeons as they remove potentially ... effective than other techniques, Italian researchers report at the ... 2011, Lugano, Switzerland. Dr Luca Bertolaccini, Dr Alberto ... in Cuneo, Italy, studied a technique known as radio-guided ...
... Like a bounty hunter returning escapees to custody, a cancer-fighting ... cells back to their original, stationary state, researchers report online ... activity of the p53 gene offers a potential avenue of ... central role in progression and spread of the disease, according ...
... , FRIDAY, Feb. 25 (HealthDay News) -- ... 30s and 40s who are prone to addiction problems ... looked at how personal history, family life and neighborhood ... 12-year period during their early years of marriage and ...
... , FRIDAY, Feb. 25 (HealthDay News) -- Guilt might be a ... doesn,t stop students from doing it, researchers have found. In ... Hampshire, almost half said they feel guilty about texting during class ... percent said they send at least one text message during a ...
... New Rochelle, NY, February 25, 2011Hashimoto,s thyroiditis (HT), an ... cause of hypothyroidism, but a study has suggested that ... symptoms and decrease quality of life, as described in ... published by Mary Ann Liebert, Inc. ( www.liebertpub.com ). ...
... HealthDay Reporter , FRIDAY, Feb. 25 (HealthDay News) ... assistant for minor ailments when their family doctor can,t fit ... -- a dental therapist who could perform basic dental procedures ... invasive procedures, such as extractions and oral surgery. Not ...
Cached Medicine News:Health News:Radio-guided surgery a safe and simple way to remove potentially cancerous nodules in the lung 2Health News:Protein and microRNA block cellular transition vital to metastasis 2Health News:Depression May Worsen Over Time in Addiction-Prone Women 2Health News:Hashimoto's thyroiditis can affect quality of life 2Health News:Special Assistants Making Inroads in Dentistry 2Health News:Special Assistants Making Inroads in Dentistry 3
A-Focus I & II Catheters. A-Focus steerable atrial mapping catheter. Available in 10, 12, 14 and 20 electrode configurations. (Shown with 14 electrodes)....
... patient monitoring products for hospital based ... acuity monitoring. The Envoy patient monitor ... The Enmove monitor offers a portable, ... the Envoy. The Ensemble central ...
... VERICIS PhysioLog Hemodynamic Monitoring and ... easy-to-use system for the cath lab, ... , Waveform analysis , Data collection ... , Image capture/analysis , Procedural reporting ...
A fully automated, benchtop instrument designed for high-volume urine testing, using Siemens' proven technology in dry-pad urine chemistry analysis....
Medicine Products: